376 related articles for article (PubMed ID: 11255561)
21. The search for the ideal SERM.
Arun B; Anthony M; Dunn B
Expert Opin Pharmacother; 2002 Jun; 3(6):681-91. PubMed ID: 12036407
[TBL] [Abstract][Full Text] [Related]
22. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.
Vogelvang TE; van der Mooren MJ; Mijatovic V; Kenemans P
Drugs; 2006; 66(2):191-221. PubMed ID: 16451093
[TBL] [Abstract][Full Text] [Related]
23. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Park WC; Jordan VC
Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
[TBL] [Abstract][Full Text] [Related]
24. Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis.
Fontana A; Delmas PD
Endocrinol Metab Clin North Am; 2003 Mar; 32(1):219-32. PubMed ID: 12699300
[TBL] [Abstract][Full Text] [Related]
25. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
26. Selective estrogen receptor modulators and postmenopausal health.
Roe EB; Chiu KM; Arnaud CD
Adv Intern Med; 2000; 45():259-78. PubMed ID: 10635051
[TBL] [Abstract][Full Text] [Related]
27. [Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].
Pfeilschifter J
Orthopade; 2001 Jul; 30(7):462-72. PubMed ID: 11515185
[TBL] [Abstract][Full Text] [Related]
28. [Selective estrogen receptor modulators (SERMs) in the practice].
Nagykálnai T
Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
[TBL] [Abstract][Full Text] [Related]
29. [Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
Burckhardt P
Schweiz Med Wochenschr; 1999 Dec; 129(49):1926-30. PubMed ID: 10635085
[TBL] [Abstract][Full Text] [Related]
30. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].
Chmel R; Rob L; Strnad P
Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918
[TBL] [Abstract][Full Text] [Related]
31. Selective estrogen-receptor modulators.
Cosman F
Clin Geriatr Med; 2003 May; 19(2):371-9. PubMed ID: 12916292
[TBL] [Abstract][Full Text] [Related]
32. Selective estrogen modulators in menopause.
Gambacciani M
Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
[TBL] [Abstract][Full Text] [Related]
33. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Lewiecki EM
J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
[TBL] [Abstract][Full Text] [Related]
34. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.
Draper MW
Ann N Y Acad Sci; 2003 Nov; 997():373-7. PubMed ID: 14644844
[TBL] [Abstract][Full Text] [Related]
35. Progress in the prevention of breast cancer: concept to reality.
Jordan VC
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935
[TBL] [Abstract][Full Text] [Related]
36. Selective oestrogen receptor modulation: molecular pharmacology for the millennium.
Levenson AS; Jordan VC
Eur J Cancer; 1999 Dec; 35(14):1974-85. PubMed ID: 10711240
[TBL] [Abstract][Full Text] [Related]
37. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
38. Chemoprevention of breast cancer in the older patient.
Minton SE
Hematol Oncol Clin North Am; 2000 Feb; 14(1):113-30. PubMed ID: 10680075
[TBL] [Abstract][Full Text] [Related]
39. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
[TBL] [Abstract][Full Text] [Related]
40. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
